# C4 Therapeutics

**Canonical:** https://apis.io/providers/c4-therapeutics/  
**Website:** https://c4therapeutics.com/  
**APIs profiled:** 1

C4 Therapeutics is a biopharmaceutical company focused on developing novel targeted protein degradation therapies for cancer. The company leverages its proprietary TORPEDO® platform to discover and advance degraders such as CFT8919 and Cemsidomide, aiming to address unmet medical needs. It provides information for patients, healthcare providers, investors, and partners through its corporate website and investor relations portal.

## Kin Score — 11.9 / 100 (emerging)

Scored 2026-10-09 under rubric 0.23.0.

| Facet | Score |
|---|---|
| Discoverability | 55.4 |
| Contract Quality | 0.0 |
| Contract Governance | 0.0 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 11.9 |
| Access Clarity | 21.1 |

Regulatory layer — **Horizontal (data, software, accessibility, platform)**: 13.7 (matched via fallback).

## Agent readiness — 3.1 (human-only)

| Dimension | Value |
|---|---|
| Spec Presence | no |
| Agentic Access | no |
| Reversibility Documented | no |
| MCP Server | documented |
| Auth Clarity | no |
| Idempotency | no |
| Error Semantics | no |
| OpenAPI Examples | no |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | no |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |
| Delegated Identity | no |
| Protected Resource Metadata | no |
| Dynamic Client Registration | no |
| Agentic Commerce | no |

## APIs (1)

- **C4 Therapeutics API** — API information for C4 Therapeutics is documented on their "Our Science" page.

## Security (1)

- **C4 Therapeutics Domain Security** — TLSv1.3 · DMARC

## Tags

Company, Biopharma, Cancer, Targeted Protein Degradation, TORPEDO Platform

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/c4-therapeutics/). Scores are computed from the provider's own public artifacts under a published rubric.